YieldMax AMZN Option Income Strategy ETF vs Becton Dickinson and Co — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.35, while Becton Dickinson and Co trades at $179.13 (market cap $49.41B). The key difference: Becton Dickinson and Co pays a 2.32% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | BDX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $185.39 |
52-Week Low | $9.98 | $138.62 |
Market Cap | — | $49.41B |
Enterprise Value | — | $65.51B |
Dividend Yield | — | 2.32% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →